Zebec Network expands its payroll ecosystem with Payro Finance partnership
Zebec Network has expanded its payroll capabilities by partnering with Payro Finance to integrate on-demand payroll lending.
- Zebec Network has partnered with Payro Finance to integrate real-time stablecoin payroll with instant on-demand payroll loans.
- The Payro collaboration follows Zebec’s TurnkeyHQ integration, which allows employees to receive stablecoin salaries directly within their payroll dashboards.
- Zebec has recently enhanced compliance with SOC 2 certification and is pursuing MiCA and ISO 27001 standards to support global payroll operations.
Zebec Network ( ZBCN ) today announced a strategic partnership with Payro Finance , a payroll-focused funding solution licensed and compliant across all 50 U.S. states, to integrate real-time stablecoin payroll with on-demand payroll lending.
The integration builds on Zebec’s existing payroll platform, which already allows companies to stream salaries in real-time using USDC stablecoin. By incorporating Payro’s lending tools, Zebec’s clients can now access instant payroll loans to cover short-term cash flow gaps, ensuring employees are paid on time regardless of financial constraints.
Zebec and Payro will host an upcoming Spaces on X to discuss the partnership and its impact on global payroll solutions.
Zebec Network continues to expand its payroll ecosystem
Zebec’s latest partnership with Payro Finance comes on the heels of another collaboration in its payroll ecosystem. A couple of days ago, Zebec announced that it had partnered with TurnkeyHQ to power embedded wallet infrastructure in its integrations with major U.S. payroll systems. Through Turnkey, employees can receive salaries in stablecoins directly within their payroll dashboards, alongside traditional bank transfers.
In addition to its growing partnership network, including recent deals with Gatenox and the acquisition of Science Card , Zebec is actively strengthening compliance efforts. The company is now SOC 2-compliant , joining a select group of crypto projects that have reached this standard. Zebec is also pursuing MiCA compliance under the EU framework and targeting ISO 27001 certification for information security management.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
